Literature DB >> 12675851

Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.

Nosratola D Vaziri1, Tadashi Sato, Kaihui Liang.   

Abstract

BACKGROUND: Imai rats exhibit spontaneous focal glomerulosclerosis (FGS), which is marked by heavy proteinuria, severe hyperlipidemia, and progressive renal insufficiency beginning at 8 to 10 weeks of age. In an earlier study, we reported severe skeletal muscle and adipose tissue lipoprotein lipase, and very low-density lipoprotein (VLDL) receptor deficiencies, which account for elevated plasma VLDL and triglycerides in Imai rats at 34 weeks of age. In this study, we investigated key factors involved in cholesterol metabolism.
METHODS: Male Imai and Sprague-Dawley control rats were fed a regular rat chow and observed from age 8 through 34 weeks. Hepatic 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase, cholesterol 7alpha-hydroxylase, low-density lipoprotein (LDL) receptor and acyl Co A:cholesterol acyltransferase (ACAT) were measured by Western blot and plasma lecithin:cholesterol acyltransferase (LCAT) protein was measured by enzyme-linked immunosorbent assay (ELISA).
RESULTS: At 34 weeks of age, the Imai rats showed severe proteinuria, hypoalbuminemia, 60% reduction in glomerular filtration rate (GFR), elevated plasma total and LDL cholesterol and LDL/high-density lipoprotein (HDL) ratio. Imai rats showed a twofold elevation of hepatic HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis, but no significant change in cholesterol 7alpha-hydroxylase, the rate-limiting enzyme in cholesterol catabolism to bile acids. This was accompanied by and largely due to a threefold down-regulation of hepatic LDL receptor, which limits hepatic uptake of LDL; and a threefold up-regulation of hepatic ACAT (P < 0.01), which augments esterification of hepatocyte free cholesterol, thus, limiting cholesterol-mediated feedback regulation of cholesterol synthesis and catabolism. Moreover, plasma LCAT concentration was severely depressed (by fourfold) in Imai rats. This abnormality can impair HDL-mediated cholesterol transport from extrahepatic tissues to the liver.
CONCLUSION: The study revealed marked abnormalities of the key proteins involved in regulation of hepatic cholesterol metabolism. These abnormalities can account for severe dysregulation of cholesterol metabolism in Imai rats with spontaneous FGS, which closely resembles FGS in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12675851     DOI: 10.1046/j.1523-1755.2003.00911.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

1.  The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated Hypercholesterolemia.

Authors:  Mary E Haas; Amy E Levenson; Xiaowei Sun; Wan-Hui Liao; Joseph M Rutkowski; Sarah D de Ferranti; Valerie A Schumacher; Philipp E Scherer; David J Salant; Sudha B Biddinger
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.

Authors:  Nosratola D Vaziri
Journal:  Kidney Int       Date:  2016-04-26       Impact factor: 10.612

Review 3.  Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins.

Authors:  Roberto Scarpioni; Marco Ricardi; Vittorio Albertazzi; Luigi Melfa
Journal:  World J Nephrol       Date:  2012-12-06

Review 4.  Dyslipidemia in patients with chronic kidney disease.

Authors:  Matthew R Hager; Archana D Narla; Lisa R Tannock
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis.

Authors:  George A Kaysen; Kirsten L Johansen; Glenn M Chertow; Lorien S Dalrymple; John Kornak; Barbara Grimes; Tjien Dwyer; Alexander W Chassy; Oliver Fiehn
Journal:  J Ren Nutr       Date:  2015-03-19       Impact factor: 3.655

Review 6.  Causes of dysregulation of lipid metabolism in chronic renal failure.

Authors:  Nosratola D Vaziri
Journal:  Semin Dial       Date:  2009 Nov-Dec       Impact factor: 3.455

Review 7.  High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.

Authors:  Georges Khoueiry; Mokhtar Abdallah; Faisal Saiful; Nidal Abi Rafeh; Muhammad Raza; Tariq Bhat; Suzanne El-Sayegh; Kamyar Kalantar-Zadeh; James Lafferty
Journal:  Int Urol Nephrol       Date:  2013-02-27       Impact factor: 2.370

8.  Reverse cholesterol transport pathway in experimental chronic renal failure.

Authors:  Hamid Moradi; Jun Yuan; Zhemin Ni; Keith Norris; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2009-03-24       Impact factor: 3.754

Review 9.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

Review 10.  Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.

Authors:  Roy O Mathew; Robert S Rosenson; Radmila Lyubarova; Rafia Chaudhry; Salvatore P Costa; Sripal Bangalore; Mandeep S Sidhu
Journal:  Cardiovasc Drugs Ther       Date:  2021-06       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.